Belgian biopharmaceutical company Ablynx has developed unique new-generation bispecific therapeutic nanobodies ozoralizumab (ATN-103) and vobarilizumab (ALX0061) for the treatment of RA, the first humanized bispecific nanobodies, which neutralize TNF and IL-6R, respectively, and also bind to human serum albumin to increase the half-life. This evidence concerns the gene IL6R and rheumatoid arthritis.